PropThink: ACOR Prints Strong 3Q; Estimates Likely To Rise and Stock To Work Higher

[ACN Newswire] – By David MoskowitzAcorda Therapeutics (NASDAQ:ACOR) reported 3Q 2012 revenues and EPS of $77.4 million and $0.24, vs. the Consensus estimates of $75.1 million and $0.10, respectively. Sales of lead product … more

View todays social media effects on ACOR

View the latest stocks trending across Twitter. Click to view dashboard